The Conamax platform is a robustly fermentable engineered eukaryotic microbe capable of producing biopharmaceuticals with competitive cost and faster timeline. It is uniquely suited for making antibodies and promises to achieve productivity upward of 1 g/L/day. One of the most exciting features of this host organism is its ability to express glycoproteins harboring homogenous glycostructures which promote the desired immune cell functions. It is also advantaged by its ability to tolerate the engineering required to customize these glycostructures while preserving the microbe’s robustness.